DWTX

Dogwood Therapeutics, Inc. Common Stock
DWTX
Market cap $8.16M

4.27 USD

+0.54

14.48%

At close Apr 17, 4:00 PM EDT

After hours

4.36

+0.09

2.11%

1 day

14.48%

5 days

41.86%

1 month

-29.89%

3 months

128.34%

6 months

6.48%

Year to date

70.12%

1 year

846.99%

5 years

-74.45%

10 years

-74.45%

About: Dogwood Therapeutics Inc, formerly Virios Therapeutics Inc, is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a virus-triggered abnormal immune response, such as fibromyalgia (FM) and long COVID (LC). Its product candidates include IMC-1 and IMC-2. IMC-1 is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.

Employees: 12

Healthcare Biotechnology

0

Funds holding %

of 7,407 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

1.52% less ownership

Funds ownership: 3.83% [Q3] → 2.31% (-1.52%) [Q4]

58% less capital invested

Capital invested by funds: $180K [Q3] → $76.5K (-$104K) [Q4]

58% less funds holding

Funds holding: 24 [Q3] → 10 (-14) [Q4]

93% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 14

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 9

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for DWTX.

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about DWTX published over the past 30 days

Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance

ATLANTA, April 11, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders, today announced that it has received written confirmation from Nasdaq that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders' equity of $2.5 million.

Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance

ATLANTA, April 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders today announced it believes it has regained compliance with the minimum stockholders' equity requirement as set forth in Nasdaq Listing Rule 5550(b)(1). DWTX Chairman and CEO Greg Duncan stated, “We appreciate the consideration Nasdaq has shown Dogwood Therapeutics, Inc.” He continued, “The Company has a strong cash position of $17.5 million as of the end of Q1, with no debt, better positioning the Company to advance its continued mission to build shareholder value.

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

-Dogwood Therapeutics, Inc. commenced dosing of patients in the Halneuron® Chemotherapy Induced Neuropathic Pain (“CINP”) Phase 2b Trial -

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

Opioid-free and addiction-free pain treatment therapy could address $1.5B worldwide CINP market Opioid-free and addiction-free pain treatment therapy could address $1.5B worldwide CINP market

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Proceeds from today's financing, when added to existing cash, fund operations through Q1 2026 The Company is planning to announce interim data from its ongoing Halneuron ® Phase 2b chemotherapy induced neuropathic pain (“CINP”) trial in Q4 2025 ATLANTA, March 13, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a development-stage biopharmaceutical company focused on advancing first-in-class, non-opioid, treatments for chronic and acute pain, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 578,950 shares of common stock at an offering price of $8.26 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The gross proceeds for the offering are expected to be approximately $4.8 million before deducting placement agent fees and other offering expenses.

Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

See News Rankings

Charts implemented using Lightweight Charts™